• Osteopore to issue $500,000 in additional Tranche 1 convertible notes
• Funds to be used for business operations and future developments
• Convertible notes part of $20 million facility with Advance Opportunities Fund

Osteopore Limited, an Australian-Singaporean regenerative medicine company, has announced the further drawdown of Tranche 1 of its redeemable convertible notes facility. The company had previously entered into a $20 million convertible note subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I, to be drawn down in four equal tranches of $5 million each. In the latest announcement, Osteopore confirms that the subscribers have subscribed for an additional 2 equal sub-tranches (ST15 and ST16) of Tranche 1 notes, for an aggregate nominal amount of $500,000. This follows previous drawdowns of $2 million in February 2025 and $1 million in April 2025 under Tranche 1. The funds raised from the issue of the convertible notes will be used to support Osteopore's ordinary course of business activities as well as future developments, projects and investments as new opportunities arise. The company remains focused on commercializing its 3D-printed biomimetic and bioresorbable implant products that stimulate natural bone healing.